---
schema_version: "secwatch.filing_event.v1"
accession: "0001851734-22-000600"
form_type: "8-K"
ticker: "NAGE"
cik: "0001386570"
company_name: "Niagen Bioscience, Inc."
filed_at: "2022-10-11T23:59:59+00:00"
generated_at: "2026-06-23T04:19:12.182761+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ChromaDex expands Nestlé Health Science supply deal to supplements; Nestlé invests $5M

## Summary
- New 5-year supply agreement gives Nestlé non-exclusive rights to sell Niagen in dietary supplements, medical nutrition, and functional foods.
- Nestlé commits to initial $1.975M Niagen purchase in 2022; ChromaDex eligible for low-single-digit royalties and low-seven-figure milestone payments.
- Nestlé purchases 3,816,794 shares of CDXC at ~$1.31/share for $5M in a registered direct offering.
- Agreement expands prior 2018 deal; term automatically extends if minimum purchase met.

## SEC filing metadata
- accession: 0001851734-22-000600
- form_type: 8-K
- ticker: NAGE
- cik: 0001386570
- company_name: Niagen Bioscience, Inc.
- filed_at: 2022-10-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1386570/000185173422000600/0001851734-22-000600-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1386570/000185173422000600/cdxc20221007_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001851734-22-000600
- JSON: https://secwatch.observer/filing/0001851734-22-000600.json
- Plain text: https://secwatch.observer/filing/0001851734-22-000600.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.